Mitomycin Medac

Mitomycin, the active ingredient in Mitomycin Medac, is an antineoplastic (alkylating) agent presented as a sterile powder for intravenous and intravesical use. It is employed in the treatment of bladder cancer and various solid tumours, administered by healthcare professionals in hospital or oncology settings.

GNH USA supplies Mitomycin Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mitomycin Medac is used as an alkylating chemotherapy agent for several malignant conditions.

- Bladder cancer (intravesical): reduces tumour recurrence after transurethral resection. - Gastric cancer (systemic): part of combination regimens to improve response rates. - Non‑small cell lung cancer (systemic): incorporated in multi‑drug protocols for advanced disease.

Mitomycin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Fatigue or weakness - Alopecia (hair loss) - Myelosuppression (low blood counts) - Diarrhoea - Mild renal impairment

Serious or Rare Side Effects: - Severe bone‑marrow failure - Life‑threatening infection (sepsis) - Pulmonary toxicity (interstitial pneumonitis) - Hemolytic‑uremic syndrome - Acute renal failure - Anaphylactic or severe allergic reactions

Mitomycin requires careful monitoring and specific safety measures before and during therapy. - Monitor blood counts: perform regular complete blood count tests to detect myelosuppression. - Assess renal function: evaluate serum creatinine and adjust therapy if impairment is present. - Avoid in patients with known hypersensitivity: discontinue immediately if allergic signs appear. - Use caution in pregnancy: risk unknown; avoid unless benefits outweigh potential harm. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mitomycin can interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Concurrent use with other alkylating agents: may increase myelosuppression. - Simultaneous radiotherapy: can enhance tissue toxicity.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs (e.g., cisplatin): monitor renal parameters. - Hepatotoxic agents (e.g., methotrexate): watch liver function tests. - Strong CYP450 inhibitors: may raise systemic exposure to mitomycin.